These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 22289835)

  • 1. [The prediction of immunogenicity of therapeutic proteins].
    Maillère B; Delluc S; Ravot G
    Med Sci (Paris); 2012 Jan; 28(1):82-8. PubMed ID: 22289835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of protein therapeutics.
    De Groot AS; Scott DW
    Trends Immunol; 2007 Nov; 28(11):482-90. PubMed ID: 17964218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunogenicity of therapeutic antibodies].
    Stas P; Lasters I
    Med Sci (Paris); 2009 Dec; 25(12):1070-7. PubMed ID: 20035681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathophysiology of autoimmune diseases.
    Boitard C
    Klin Wochenschr; 1990; 68 Suppl 21():1-9. PubMed ID: 1973964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors.
    Delluc S; Ravot G; Maillere B
    FASEB J; 2011 Jun; 25(6):2040-8. PubMed ID: 21368101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics.
    Wullner D; Zhou L; Bramhall E; Kuck A; Goletz TJ; Swanson S; Chirmule N; Jawa V
    Clin Immunol; 2010 Oct; 137(1):5-14. PubMed ID: 20708973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
    Garcia Casado J; Janda J; Wei J; Chapatte L; Colombetti S; Alves P; Ritter G; Ayyoub M; Valmori D; Chen W; Lévy F
    Eur J Immunol; 2008 Jul; 38(7):1867-76. PubMed ID: 18546142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of experimental autoimmune encephalomyelitis in Lewis rats by antibodies against CD2.
    Jung S; Toyka K; Hartung HP
    Eur J Immunol; 1995 May; 25(5):1391-8. PubMed ID: 7539758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin enhances immune responses in mice.
    Katz O; Gil L; Lifshitz L; Prutchi-Sagiv S; Gassmann M; Mittelman M; Neumann D
    Eur J Immunol; 2007 Jun; 37(6):1584-93. PubMed ID: 17458859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.
    Sakaguchi S; Sakaguchi N; Asano M; Itoh M; Toda M
    J Immunol; 1995 Aug; 155(3):1151-64. PubMed ID: 7636184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental autoimmune hearing loss.
    Billings P
    J Clin Invest; 2004 Apr; 113(8):1114-7. PubMed ID: 15085190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific inhibition of CD4+ T lymphocytes by a hybrid antibody.
    Qi Y; Staerz UD
    Nat Biotechnol; 1998 Mar; 16(3):271-5. PubMed ID: 9528008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations.
    Chamberlain P
    Bioanalysis; 2013 Mar; 5(5):561-74. PubMed ID: 23425272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B-1 cells and naturally occurring antibodies: influencing the immunogenicity of recombinant human therapeutic proteins?
    Sauerborn M; Schellekens H
    Curr Opin Biotechnol; 2009 Dec; 20(6):715-21. PubMed ID: 19892544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological activities on T lymphocytes of a baculovirus-expressed chimeric recombinant IgG1 antibody with specificity for the CDR3-like loop on the D1 domain of the CD4 molecule.
    Troadec S; Bès C; Chentouf M; Nguyen B; Briant L; Jacquet C; Chebli K; Pugnière M; Roquet F; Cerutti M; Chardès T
    Clin Immunol; 2006 Apr; 119(1):38-50. PubMed ID: 16426893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of CTLA-4 decreases the generation of multifunctional memory CD4+ T cells in vivo.
    Rudolph M; Hebel K; Miyamura Y; Maverakis E; Brunner-Weinzierl MC
    J Immunol; 2011 May; 186(10):5580-9. PubMed ID: 21478403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates.
    De Groot AS; McMurry J; Moise L
    Curr Opin Pharmacol; 2008 Oct; 8(5):620-6. PubMed ID: 18775515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humanized antibodies as potential drugs for therapeutic use.
    Merluzzi S; Figini M; Colombatti A; Canevari S; Pucillo C
    Adv Clin Path; 2000 Apr; 4(2):77-85. PubMed ID: 11080787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical considerations for calculation of immunogenicity screening assay cut points.
    Hoffman D; Berger M
    J Immunol Methods; 2011 Oct; 373(1-2):200-8. PubMed ID: 21906599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant T cell receptor molecules can prevent and reverse experimental autoimmune encephalomyelitis: dose effects and involvement of both CD4 and CD8 T cells.
    Kumar V; Coulsell E; Ober B; Hubbard G; Sercarz E; Ward ES
    J Immunol; 1997 Nov; 159(10):5150-6. PubMed ID: 9366445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.